These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16627990)

  • 1. Human tumor mutants in the p110alpha subunit of PI3K.
    Liu Z; Roberts TM
    Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
    Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic mutations of PIK3CA in human cancers.
    Samuels Y; Velculescu VE
    Cell Cycle; 2004 Oct; 3(10):1221-4. PubMed ID: 15467468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
    Zhao L; Vogt PK
    Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
    Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
    Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Sep; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.
    Pang H; Flinn R; Patsialou A; Wyckoff J; Roussos ET; Wu H; Pozzuto M; Goswami S; Condeelis JS; Bresnick AR; Segall JE; Backer JM
    Cancer Res; 2009 Dec; 69(23):8868-76. PubMed ID: 19903845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
    Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
    Huang CH; Mandelker D; Gabelli SB; Amzel LM
    Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Burke JE
    Front Immunol; 2018; 9():575. PubMed ID: 29616047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
    Ligresti G; Militello L; Steelman LS; Cavallaro A; Basile F; Nicoletti F; Stivala F; McCubrey JA; Libra M
    Cell Cycle; 2009 May; 8(9):1352-8. PubMed ID: 19305151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
    Zhao L; Vogt PK
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2652-7. PubMed ID: 18268322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear translocation of p85β promotes tumorigenesis of PIK3CA helical domain mutant cancer.
    Hao Y; He B; Wu L; Li Y; Wang C; Wang T; Sun L; Zhang Y; Zhan Y; Zhao Y; Markowitz S; Veigl M; Conlon RA; Wang Z
    Nat Commun; 2022 Apr; 13(1):1974. PubMed ID: 35418124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus.
    Jenkins ML; Ranga-Prasad H; Parson MAH; Harris NJ; Rathinaswamy MK; Burke JE
    Nat Commun; 2023 Jan; 14(1):181. PubMed ID: 36635288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-specific mutations in PIK3CA are oncogenic in vivo.
    Bader AG; Kang S; Vogt PK
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1475-9. PubMed ID: 16432179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
    Dbouk HA; Pang H; Fiser A; Backer JM
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
    Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
    Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
    Jaiswal BS; Janakiraman V; Kljavin NM; Chaudhuri S; Stern HM; Wang W; Kan Z; Dbouk HA; Peters BA; Waring P; Dela Vega T; Kenski DM; Bowman KK; Lorenzo M; Li H; Wu J; Modrusan Z; Stinson J; Eby M; Yue P; Kaminker JS; de Sauvage FJ; Backer JM; Seshagiri S
    Cancer Cell; 2009 Dec; 16(6):463-74. PubMed ID: 19962665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.